Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Toronto Stock Exchange  >  Transition Therapeutics Inc    TTH   CA8937162094

 SummaryChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Toronto Stock Exchange
02/03/2016 02/04/2016 02/05/2016 02/09/2016 02/11/2016 Date
1.39 1.36 1.34 1.3 1.26 Last
5600 4273 1600 6600 430 Volume
+2.21% -2.16% -1.47% -2.99% -3.08% Change
Financials ( CAD)
Sales 2016 2,50 M
EBIT 2016 -12,3 M
Net income 2016 -13,4 M
Debt 2016 -
Yield 2016 -
Sales 2017 2,50 M
EBIT 2017 -11,5 M
Net income 2017 -13,4 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 19,6x
Capi. / Sales 2017 19,6x
Capitalization 49,0 M
More Financials
Company
Transition Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapeutics for disease indications with large markets.It operates through research and development of therapeutic agents segment.The company's products include ELND005 for the treatment of alzheimer's... 
Sector
Pharmaceuticals
Calendar
05/10Earnings Release
More about the company
Latest news on TRANSITION THERAPEUTICS IN
02/09 TRANSITION THERAPEUTICS : Announces Second Quarter Fiscal 2016 Financial Results
02/05 TRANSITION THERAPEUTICS : to Hold Conference Call on Second Quarter Fiscal 2016 ..
02/01 TRANSITION THERAPEUTICS : Announces Top Line Phase 2 Clinical Study Results of D..
01/06 TRANSITION THERAPEUTICS : Announces Annual General Meeting Voting Results
2015 TRANSITION THERAPEUTICS : to Host Investor Day November 23 in New York
2015 TRANSITION THERAPEUTICS : Announces First Quarter Fiscal 2016 Financial Results
2015 TRANSITION THERAPEUTICS : to Hold Conference Call on First Quarter Fiscal 2016 F..
2015 TRANSITION THERAPEUTICS : Announces Presentation of ELND005 Phase 2/3 Clinical S..
More news
Sector news : Biopharmaceuticals
10:05aDJLILLY : U.K. Court Rules in Opponent's Favor on Alimta Patent
09:56aDJLILLY : U.K. Court Rules in Opponent's Favor on Alimta Patent
09:36a NOVARTIS : Sandoz Acquires Rights of Biosimilar Infliximab from Pfizer
More sector news : Biopharmaceuticals
News from SeekingAlpha
02/09 Transition Therapeutics' (TTHI) CEO Dr. Tony Cruz on Q2 2016 Results - Earnin..
02/09 Transition Therapeutics reports FQ2 results
02/01 Midday Gainers/ Losers
02/01 Transition's type 2 diabetes candidate shows positive results in mid-stage st..
2015 Eli Lilly Can Save Transition Therapeutics Inc.


Comments 
Advertisement
Chart TRANSITION THERAPEUTICS IN
Duration : Period :
Transition Therapeutics In Technical Analysis Chart | TTH | CA8937162094 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions